Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Z Shao

Showing results (331-340 of 350) with videos related to

Pageof 35
Sort By:
The American Journal of Gastroenterology|September 19, 2012
A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipationSatish Rao, Anthony J Lembo, Steven J Shiff, et al.
The New England Journal of Medicine|August 12, 2011
Two randomized trials of linaclotide for chronic constipationAnthony J Lembo, Harvey A Schneier, Steven J Shiff, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 3, 2015
Laboratory diagnosis, clinical management and infection control of the infections caused by extensively drug-resistant Gram-negative bacilli: a Chinese consensus statement, X Guan, L He, et al.
Cell Death and Differentiation|February 27, 2016
Effects of genetic correction on the differentiation of hair cell-like cells from iPSCs with MYO15A mutationJ-R Chen, Z-H Tang, J Zheng, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|July 31, 2009
VRQ397 (CRAVKY): a novel noncompetitive V2 receptor antagonistL Rihakova, C Quiniou, F F Hamdan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Overall survival with abemaciclib in early breast cancerS Johnston, M Martin, J O'Shaughnessy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 5, 2026
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trialR Dent, Z Shao, P Schmid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 8, 2018
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017G Curigliano, H J Burstein, E P Winer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et alP Dubsky, G Curigliano, H J Burstein, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 26, 2017
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017G Curigliano, H J Burstein, E P Winer, et al.
Pageof 35

Showing results (331-340 of 350) with videos related to

Sort By:
Pageof 35
The American Journal of Gastroenterology|September 19, 2012
A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipationSatish Rao, Anthony J Lembo, Steven J Shiff, et al.
The New England Journal of Medicine|August 12, 2011
Two randomized trials of linaclotide for chronic constipationAnthony J Lembo, Harvey A Schneier, Steven J Shiff, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 3, 2015
Laboratory diagnosis, clinical management and infection control of the infections caused by extensively drug-resistant Gram-negative bacilli: a Chinese consensus statement, X Guan, L He, et al.
Cell Death and Differentiation|February 27, 2016
Effects of genetic correction on the differentiation of hair cell-like cells from iPSCs with MYO15A mutationJ-R Chen, Z-H Tang, J Zheng, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|July 31, 2009
VRQ397 (CRAVKY): a novel noncompetitive V2 receptor antagonistL Rihakova, C Quiniou, F F Hamdan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Overall survival with abemaciclib in early breast cancerS Johnston, M Martin, J O'Shaughnessy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 5, 2026
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trialR Dent, Z Shao, P Schmid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 8, 2018
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017G Curigliano, H J Burstein, E P Winer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et alP Dubsky, G Curigliano, H J Burstein, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 26, 2017
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017G Curigliano, H J Burstein, E P Winer, et al.
Pageof 35